MP73-15 PROSTATE-SPECIFIC ANTIGEN HALF-LIFE IDENTIFIED AT THE FIRST FOLLOW UP TIME IS AN EARLY PROGNOSTIC FACTOR OF NEWLY DIAGNOSED METASTATIC PROSTATE CANCER

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Ki Hong Kim ◽  
Kyung Seok Han ◽  
Sung Joon Hong
2005 ◽  
Vol 72 (3) ◽  
pp. 325-330
Author(s):  
A. Kiper ◽  
O. Yigitbasi ◽  
A. Imamoglu ◽  
C. Tuygun ◽  
C. Turan

The changes in serum prostate-specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockade for metastatic prostate cancer. Materials and methods One hundred and forty-nine patients followed-up in our department were classified into four groups based on PSA changes. Group 1, those with a normalization of PSA levels within the 1st 3 months; group 2, those with a normalization of PSA levels between months 3 and 6; group 3, those with a reduction in PSA levels, but not reaching the normal range; group 4, those with no reduction in PSA levels. The gleason scores and the number of bone metastases were also compared between the groups. Results The time to progression was significantly delayed in group 1 (mean: 23.3 months) compared to that of group 2 (mean: 16.9 months) (p<0.02). The time to progression in group 3 (mean: 8.45 months) was significantly shorter compared to groups 1 and 2 (p<0.001). In addition, in patients with gleason scores 5–7 (grade 2) and gleason scores >7 (grade 3) and in group 1, the time to progression (mean: 21.2 months) was significantly delayed compared to those with the same gleason scores but in group 2 (mean: 13.4 months) (p<0.001). Conclusion The reduction in PSA levels is more important than gleason scores in determining the time to progression. Early normalization of PSA levels delays the time to progression, and when combined with gleason scores, PSA is an important prognostic factor in predicting the success of the therapy.


2005 ◽  
Vol 5 ◽  
pp. 118-124
Author(s):  
Ahmet Kiper ◽  
Orhan Yiğitbasi ◽  
Abdurrahim Imamoglu ◽  
Can Tuygun ◽  
Celaleddin Turan

The changes in serum prostate-specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockage for metastatic prostate cancer. A total of 149 patients followed in our department were classified into 4 groups on the basis of PSA changes: group 1, those with normalisation of PSA levels within the first 3 months; group 2, those with normalisation of PSA between months 3 and 6; group 3, those with a decrease in PSA, but not reaching normal range; group 4, those with no decrease. The gleason scores and the number of bone metastases were also compared between the groups. Again time to progression in patients with Gleason scores 5-7 (grade 2) and over 7 (grade 3) whose PSA levels decreased between first and 3rd months (mean 21.2 months) were significantly longer than the patients with same gleason scores whose PSA levels decreased between 3rd and 6th months (mean 13.4 months) (p < 0.001). The decrease in PSA level is more important than gleason scores in determining the time to progression. Early normalisation of PSA delays the time to progression and when combined with gleason scores, PSA is an important prognostic factor in predicting the success of the therapy.


2020 ◽  
Author(s):  
Yen-Chi Lin ◽  
Po-Hung Lin ◽  
I-Hung Shao ◽  
Yuan-Cheng Chu ◽  
Hung-Cheng Kan ◽  
...  

Abstract Background The present study aimed to analyse the effects of androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic castration-naïve prostate cancer (mCNPC) and explore predictors, particularly prostate-specific antigen (PSA) kinetics, associated with poor prognosis according to tumor volume, a new sub-classification of metastatic prostate cancer established by the CHAARTED trial.Methods We reviewed 648 patients with newly diagnosed mCNPC receiving ADT at Chang Gung Memorial Hospital from January 2007 to December 2016. Basic characteristics and PSA kinetics profile were subsequently evaluated.Results Among patients with high-volume disease, those with faster time to PSA nadir (TTN) (< 7 months), higher PSA nadir (≥ 2 ng/mL), and faster PSA doubling time (PSADT) (< 2 months) had higher risk for faster disease progression or shorter overall survival (OS) compared to those with slower TTN (> 7 months), lower PSA nadir (< 2 ng/mL), and slower PSADT (> 2 months). Multivariate analysis of those with low-volume disease showed that only PSADT (< 4 months) was tended to be associated with faster disease progression or shorter OS.Conclusions PSA kinetics are effective clinical predictors for risk of disease progression and survival. Moreover, various PSA kinetics should be monitored according to tumor volume.


2021 ◽  
pp. 284-289
Author(s):  
Hiroyuki Yoshitake ◽  
Shoji Oura ◽  
Tomoyuki Yamaguchi ◽  
Shinichiro Makimoto

An 83-year-old man with core needle biopsy-proven Gleason score 5 prostate cancer had received radiotherapy including 18 Gy brachytherapy to the prostate cancer, leading to no locoregional and distant recurrence for more than 5 years with the normalization of elevated prostate-specific antigen (PSA) level before the radiotherapy. Due to the enlargement of coexisting ground glass nodule (GGN) in the left lung from 1 to 2.1 cm, the patient underwent wide resection of the GGN 7 years later. Under the diagnosis of adenocarcinoma in situ of the lung, follow-up computed tomography 6 months after the wide resection showed a rapid enlargement of a solid nodule having been judged as a presumed inflammatory nodule in the middle lobe, highly suggesting a malignant neoplasm of the lung. Due to both the tall columnar atypical cells with trabecular pattern on frozen section and no elevation of serum PSA level, we judged the nodule as a primary adenocarcinoma of the lung and further resected the middle lobe with lymph node dissection. Immunostaining of the tumor showed all the CK7, CK20, TTF-1, napsin A, synaptophysin, chromogranin, CD56, CDX2, p53, beta-catenin, and MUC2 negative, and PSA highly positive, clearly showing the solid nodule as a solitary lung metastasis of the prostate cancer. Physicians should note the possible solitary lung metastasis of prostate cancer, especially bearing indolent biology, with no elevation of the PSA level even after the completion of standard 5-year follow-up.


Sign in / Sign up

Export Citation Format

Share Document